Competitive Technologies, Inc.

I'll research this company before writing the profile.

Let me look into the specific cases and verify the company's later history.

Let me verify the company's later corporate history and current status.

Competitive Technologies, Inc. — company profile

Overview. Competitive Technologies, Inc. ("CTT") was incorporated in Delaware in 1971, succeeding an Illinois corporation incorporated in 1968, and is headquartered in Fairfield, Connecticut. It was long a small, publicly traded micro-cap, listed on NYSE Amex (ticker CTT) until its delisting, after which it traded over the counter on the OTCQB/OTCQX under CTTC. Effective August 20, 2014, the company changed its name to Calmare Therapeutics Incorporated, which remains the current corporate name. It is not a subsidiary of a larger parent. Verified current headcount and revenue figures are not available; a 1998 Hartford Courant business profile listed 23 total employees and $2.48 million in 1997 revenue, and SEC filings from the late 2000s described recurring losses and going-concern doubts, so it should be treated as a small OTC-traded company.

Operations. Historically CTT was a technology-transfer and licensing intermediary: technology and market assessment, patent application and prosecution, patent enforcement, licensing, license management, and royalty distribution for university and federal-agency clients (its roots go back to University Patents, Inc., licensing agent for institutions such as the University of Colorado and Lehigh University). Its licensed technologies spanned life sciences, diagnostics (notably homocysteine assays), electronics, and nanomaterials. Later, the company shifted to medical devices, becoming the exclusive worldwide distributor of the Calmare Pain Therapy Device (Scrambler Therapy, licensed from Italian inventor Giuseppe Marineo), sold to medical practices and via a GSA contract. It also held a majority interest in subsidiary Vector Vision, Inc. (wound-care imaging).

Litigation posture. CTT is best characterized as an operating/licensing company rather than a pure assertion entity, and it was an active two-way litigant around 2000–2001. Its two tracked cases are mirror images: it appeared as a plaintiff in Delaware asserting university-origin patents, and as a defendant in the corresponding declaratory-judgment action in New York. It had only two appearances and neither case was in the Eastern District of Texas.

Notable cases. In Applera Corporation et al. v. Affymetrix, Inc. (D. Del., filed July 5, 2000), Applera and CTT sued Affymetrix for infringement of five "Caruthers" polynucleotide-synthesis patents; CTT claimed title to the patents while PE Corporation (N.Y.) held exclusive enforcement rights. The Delaware action was dismissed in September 2000 for lack of subject-matter jurisdiction, and the dispute continued as Affymetrix, Inc. v. PE Corporation (N.Y.) et al. in the S.D.N.Y. (filed January 2001), where Affymetrix named CTT on declaratory-judgment, antitrust, and unfair-competition counts.